Innate Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	2.79	12.62	51.9	49.58	12.11
Other Revenue	6.22	7.5	9.74	8.09	12.59
Revenue	9.01	20.12	61.64	57.67	24.7
Revenue Growth	-55.25%	-67.36%	6.88%	133.47%	-64.59%
Cost of Revenue	43.62	51.98	56.02	51.66	47
Gross Profit	-34.62	-31.86	5.62	6.01	-22.3
Selling, General & Admin	19.39	19.72	18.29	22.44	25.52
Operating Expenses	19.39	19.72	18.29	22.44	25.52
Operating Income	-54.01	-51.58	-12.67	-16.43	-47.83
Interest Expense	-0.44	-0.57	-0.64	-0.29	-0.31
Interest & Investment Income	1.32	2.44	3.18	0.55	0.33
Currency Exchange Gain (Loss)	3.2	-1.75	0.91	0.83	1.25
Other Non Operating Income (Expenses)	0.75	1.98	1.65	-1.63	1.08
EBT Excluding Unusual Items	-49.18	-49.47	-7.57	-16.97	-45.48
Asset Writedown	-	-	-	-41	-
Pretax Income	-49.18	-49.47	-7.57	-57.97	-45.48
Earnings From Continuing Operations	-49.18	-49.47	-7.57	-57.97	-45.48
Earnings From Discontinued Operations	-	-	-	-0.13	-7.33
Net Income	-49.18	-49.47	-7.57	-58.1	-52.81
Net Income to Common	-49.18	-49.47	-7.57	-58.1	-52.81
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	90	81	80	80	80
Shares Outstanding (Diluted)	90	81	80	80	80
Shares Change	10.54%	0.74%	1.02%	0.12%	0.77%
EPS (Basic)	-0.55	-0.61	-0.09	-0.73	-0.66
EPS (Diluted)	-0.55	-0.61	-0.09	-0.73	-0.66
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-52.9	-7.29	-32.91	-19.69	-59.39
Free Cash Flow Per Share	-0.59	-0.09	-0.41	-0.25	-0.75
Gross Margin	-	-158.34%	9.12%	10.42%	-90.28%
Operating Margin	-599.77%	-256.32%	-20.55%	-28.48%	-193.60%
Profit Margin	-546.11%	-245.87%	-12.28%	-100.74%	-213.78%
Free Cash Flow Margin	-587.40%	-36.22%	-53.39%	-34.14%	-240.40%
EBITDA	-53.31	-50.27	-8.53	-12.02	-43.23
EBITDA Margin	-	-249.86%	-13.84%	-20.84%	-174.99%
D&A For EBITDA	0.7	1.3	4.14	4.41	4.6
EBIT	-54.01	-51.58	-12.67	-16.43	-47.83
EBIT Margin	-	-256.32%	-20.55%	-28.48%	-193.60%
Revenue as Reported	9.01	20.12	61.64	57.67	24.7

SEC Filings: 10-K · 10-Q